Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H2 2017

  • ID: 4426926
  • Report
  • 84 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • ValiRx Plc
  • Zen-Bio Inc
  • MORE
Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Tyrosine Protein Kinase Fyn - Pipeline Review, H2 2017'; Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Fyn is an enzyme encoded by the FYN gene. It plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions.

The report 'Tyrosine Protein Kinase Fyn - Pipeline Review, H2 2017' outlays comprehensive information on the Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 2 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Metabolic Disorders, Respiratory, Cardiovascular, Hematological Disorders, Musculoskeletal Disorders and Women's Health which include indications Alzheimer's Disease, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Ovarian Cancer, Systemic Mastocytosis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alcohol Addiction, Amyotrophic Lateral Sclerosis, Asthma, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Cancer Pain, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Crohn's Disease (Regional Enteritis), Endometriosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Gastrointestinal Stromal Tumor (GIST), Gliosarcoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypereosinophilic Syndrome, Lymphangioleiomyomatosis, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Ovarian Cancer, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Metaplasia, Non-Small Cell Lung Cancer, Obesity, Oligodendroglioma, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Polycythemia Vera, Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Pulmonary Arterial Hypertension, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS) and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) targeted therapeutics.
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • ValiRx Plc
  • Zen-Bio Inc
  • MORE
Introduction

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AB Science SA

AstraZeneca Plc

Bristol-Myers Squibb Co

ValiRx Plc

Zen-Bio Inc

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Drug Profiles

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

saracatinib difumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Fyn Kinase for Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FYN Kinase for Obesity and Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Dormant Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase Fyn (Proto Oncogene Syn or Proto Oncogene c Fyn or Src Like Kinase or p59 Fyn or FYN or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight

Sep 28, 2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017

Sep 20, 2017: ValiRx Provides Update on VAL201

Sep 14, 2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment

Jul 12, 2017: AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients

Jul 10, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Sprycel (dasatinib) in Children with Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia

Jun 22, 2017: AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association

Jun 05, 2017: Early, Durable Responses Seen with Sprycel (dasatinib) in First- and Second-Line Treatment of Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML)

May 19, 2017: European Medicines Agency Validates Application for Bristol-Myers Squibb's Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia

May 18, 2017: AB Science Announces Refusal of the marketing authorisation for Masipro (masitinib)

May 18, 2017: AB Science Presents Phase 3 Data for Masitinib in Amyotrophic Lateral Sclerosis at the European Network For The Cure of ALS Annual Meeting

May 17, 2017: AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings

May 12, 2017: AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice standards

Mar 29, 2017: AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years

Mar 20, 2017: AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AB Science SA, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by Bristol-Myers Squibb Co, H2 2017

Pipeline by ValiRx Plc, H2 2017

Pipeline by Zen-Bio Inc, H2 2017

Dormant Products, H2 2017

Discontinued Products, H2 2017

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • ValiRx Plc
  • Zen-Bio Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll